Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma	Recruiting	Phase 2	2026-06-08		NCT06497530

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Guangzhou Institute of Respiratory Disease	16

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The first affiliated hospital of Guangzhou medical university	Guangzhou	China	1

Clinical trials